Management  	Management  	 NN	O
of  	of  	 IN	O
fingolimod  	fingolimod  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
The  	The  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
innovative  	innovative  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
drug  	drug  	 NN	I-NP
fingolimod  	fingolimod  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
proven  	proven  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
largest  	largest  	 JJS	O
study  	study  	 NN	B-NP
program  	program  	 NN	I-NP
in  	in  	 IN	O
multiple  	multiple  	 JJ	B-NP
sclerosis  	sclerosis  	 NNS	I-NP
( 	( 	 -LRB-	O
MS 	MS 	 NNP	B-NP
)  	)  	 -RRB-	O
demonstrating  	demonstrating  	 VBZ	O
reduced  	reduced  	 VBN	O
relapse  	relapse  	 NNS	O
and  	and  	 CC	O
reduced  	reduced  	 JJ	O
disability  	disability  	 NN	B-NP
progression  	progression  	 NN	I-NP
in  	in  	 IN	O
relapsing-remitting  	relapsing-remitting  	 NNP	O
MS  	MS  	 NNP	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
extensive  	extensive  	 JJ	B-NP
safety  	safety  	 NN	I-NP
data  	data  	 NNS	I-NP
of  	of  	 IN	O
all  	all  	 DT	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
natural  	natural  	 JJ	O
distribution  	distribution  	 NN	B-NP
pattern  	pattern  	 NN	I-NP
of  	of  	 IN	I-NP
fingolimod  	fingolimod  	 JJ	I-NP
interacting  	interacting  	 JJ	I-NP
receptors  	receptors  	 NNS	I-NP
in  	in  	 IN	O
organism 	organism 	 NN	B-NP
,  	,  	 ,	O
careful  	careful  	 JJ	O
clinical  	clinical  	 JJ	B-NP
monitoring  	monitoring  	 NN	I-NP
is  	is  	 VBZ	O
recommend  	recommend  	 VBN	O
and  	and  	 CC	O
reviewed  	reviewed  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
paper 	paper 	 NN	O
.  	.  	 .	O
Safety  	Safety  	 NNP	O
and  	and  	 CC	O
tolerability  	tolerability  	 JJ	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
clinical  	clinical  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
current  	current  	 JJ	O
post-marketing  	post-marketing  	 JJ	B-NP
experience  	experience  	 NN	I-NP
present  	present  	 NN	O
with  	with  	 IN	O
high  	high  	 JJ	O
tolerability  	tolerability  	 NN	B-NP
and  	and  	 CC	O
easy-to-perform  	easy-to-perform  	 JJ	B-NP
management  	management  	 NN	I-NP
of  	of  	 IN	I-NP
fingolimod 	fingolimod 	 NN	I-NP
.  	.  	 .	O
Here  	Here  	 RB	O
we  	we  	 PRP	O
present  	present  	 VBP	O
the  	the  	 DT	O
recommended  	recommended  	 JJ	O
management  	management  	 NN	O
of  	of  	 IN	O
fingolimod  	fingolimod  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
starting  	starting  	 VBG	O
with  	with  	 IN	O
preparatory  	preparatory  	 JJ	B-NP
steps 	steps 	 NNS	I-NP
,  	,  	 ,	O
first-dose  	first-dose  	 JJ	B-NP
application  	application  	 NN	I-NP
and  	and  	 CC	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	B-NP
period  	period  	 NN	I-NP
with  	with  	 IN	O
fingolimod 	fingolimod 	 NN	B-NP
.  	.  	 .	O
This  	This  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
fingolimod  	fingolimod  	 NN	B-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice  	practice  	 NN	I-NP
ensure  	ensure  	 VB	O
a  	a  	 DT	O
safe  	safe  	 JJ	O
treatment  	treatment  	 NN	O
algorithm  	algorithm  	 VBZ	O
using  	using  	 VBG	O
fingolimod 	fingolimod 	 NNS	B-NP
.  	.  	 .	O
We  	We  	 PRP	O
recommend  	recommend  	 VBP	O
documentation  	documentation  	 VBN	B-NP
of  	of  	 IN	I-NP
fingolimod  	fingolimod  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
registries  	registries  	 NN	I-NP
to  	to  	 TO	O
generate  	generate  	 VB	O
postmarketing  	postmarketing  	 JJ	B-NP
data  	data  	 NNS	I-NP
on  	on  	 IN	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
fingoilimod 	fingoilimod 	 NN	B-NP
.  	.  	 .	O
